We need to tenofovir alafenamide for HBV patients now in Iran!
The US Food and Drug Administration has approved tenofovir alafenamide (TAF) 25 mg once daily, for treatment of adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. Tenofovir disoproxil fumarate (TDF) has potent antiviral activity in patients with chronic HBV infection, but long-term use has been associated with renal side effects and reduced bone mineral density in some patients. TAF is a targeted prodrug of tenofovir that has antiviral efficacy similar to that of Tenofovir at a dose less than one tenth that of it.
Data show that because TAF has greater plasma stability and more efficiently delivers tenofovir to hepatocytes compared to TDF, it can be given at a lower dose, resulting in less tenofovir in the bloodstream.
In an integrated analysis of both studies, patients receiving TAF had improvements in certain bone and renal laboratory parameters compared to patients treated with TDF. Patients taking TAF also had numerically higher rates of normalization of blood serum alanine aminotransferase levels.